These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10627170)

  • 1. CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    Drug Metab Dispos; 1999 Dec; 27(12):1519-22. PubMed ID: 10627170
    [No Abstract]   [Full Text] [Related]  

  • 2. Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.
    Nakajima M; Kobayashi K; Oshima K; Shimada N; Tokudome S; Chiba K; Yokoi T
    Xenobiotica; 1999 Sep; 29(9):885-98. PubMed ID: 10548449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.
    Murray S; Odupitan AO; Murray BP; Boobis AR; Edwards RJ
    Xenobiotica; 2001 Mar; 31(3):135-51. PubMed ID: 11465391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
    Thijssen HH; Flinois JP; Beaune PH
    Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of CYP2C9 as a human liver microsomal linoleic acid epoxygenase.
    Draper AJ; Hammock BD
    Arch Biochem Biophys; 2000 Apr; 376(1):199-205. PubMed ID: 10729206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity.
    Tang C; Shou M; Rodrigues AD
    Drug Metab Dispos; 2000 May; 28(5):567-72. PubMed ID: 10772636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor.
    Ohyama K; Nakajima M; Nakamura S; Shimada N; Yamazaki H; Yokoi T
    Drug Metab Dispos; 2000 Nov; 28(11):1303-10. PubMed ID: 11038157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
    Grimm SW; Dyroff MC
    Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates.
    Mankowski DC; Lawton MP; Ekins S
    Xenobiotica; 2000 Aug; 30(8):745-54. PubMed ID: 11037108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9.
    Jones JP; He M; Trager WF; Rettie AE
    Drug Metab Dispos; 1996 Jan; 24(1):1-6. PubMed ID: 8825183
    [No Abstract]   [Full Text] [Related]  

  • 11. Substrate influence on interaction between cytochrome P450 and cytochrome b5 in microsomes.
    Jansson I; Schenkman JB
    Arch Biochem Biophys; 1996 Jan; 325(2):265-9. PubMed ID: 8561506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P4502C11 is a target of diclofenac covalent binding in rats.
    Shen S; Hargus SJ; Martin BM; Pohl LR
    Chem Res Toxicol; 1997 Apr; 10(4):420-3. PubMed ID: 9114979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation.
    Miller JL; Trepanier LA
    Eur J Clin Pharmacol; 2002 Apr; 58(1):69-72. PubMed ID: 11956677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzyloxyresorufin as a specific substrate for the major phenobarbital-inducible dog liver cytochrome P450 (P4502B11).
    Klekotka PA; Halpert JR
    Drug Metab Dispos; 1995 Dec; 23(12):1434-5. PubMed ID: 8689957
    [No Abstract]   [Full Text] [Related]  

  • 15. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions.
    Karjalainen MJ; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2006 Dec; 34(12):2091-6. PubMed ID: 16985100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluvoxamine on the pharmacokinetics of quinidine.
    Damkier P; Hansen LL; Brøsen K
    Eur J Clin Pharmacol; 1999 Aug; 55(6):451-6. PubMed ID: 10492058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
    Danie WA; Syrek M; Ryłko Z; Wójcikowski J
    Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diminished activity of testosterone-16-alpha hydroxylase in bovine liver microsomes].
    Depelchin BO
    Ann Rech Vet; 1984; 15(4):515-8. PubMed ID: 6529121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes.
    Kobayashi K; Nakajima M; Oshima K; Shimada N; Yokoi T; Chiba K
    Drug Metab Dispos; 1999 Aug; 27(8):860-5. PubMed ID: 10421611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvoxamine is a potent inhibitor of cytochrome P4501A2.
    Brøsen K; Skjelbo E; Rasmussen BB; Poulsen HE; Loft S
    Biochem Pharmacol; 1993 Mar; 45(6):1211-4. PubMed ID: 8466541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.